<table>
<thead>
<tr>
<th>Document Type</th>
<th>Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index Number</td>
<td>Registry 109</td>
</tr>
<tr>
<td>Version Number</td>
<td>1.0</td>
</tr>
<tr>
<td>Title</td>
<td>Disease status HCT CT IST Day 0</td>
</tr>
<tr>
<td>Author</td>
<td>Annelot van Amerongen</td>
</tr>
<tr>
<td>Authorised By</td>
<td>Annelot van Amerongen</td>
</tr>
<tr>
<td>Authorised On</td>
<td>22-Aug-2023</td>
</tr>
<tr>
<td>Release Date</td>
<td>22-Aug-2023</td>
</tr>
</tbody>
</table>
DISEASE STATUS AT HCT/CT/IST
Day 0

PATIENT STATUS
(All Diagnoses)

Date of HCT/CT/IST: ____/____/_____ (YYYY/MM/DD)
(or planned date of HCT/CT/IST if patient died before)

Survival status at HCT/CT/IST:
☐ Alive
☐ Died after conditioning but before HCT/CT/IST
☐ Died after apheresis but before cell infusion

Date of death: ____/____/_____ (YYYY/MM/DD)

Main cause of death:
(check only one main cause)

☐ Relapse or progression/persistent disease
☐ Secondary malignancy

☐ Cellular therapy-related

Select treatment related cause:
☐ Graft versus host disease
☐ Non-infectious complication
☐ Infectious complication:
  (select all that apply)
  ☐ Bacterial infection
  ☐ Viral infection
  ☐ Fungal infection
  ☐ Parasitic infection
  ☐ Infection with unknown pathogen

☐ HCT-related

☐ Unknown

☐ Other; specify: __________

Performance status at initiation of HCT/CT/IST (choose only one):

Type of scale used: Score:

☐ Karnofsky
☐ Lansky

☐ 10 ☐ 20 ☐ 30 ☐ 40 ☐ 50 ☐ 60 ☐ 70 ☐ 80 ☐ 90 ☐ 100

☐ ECOG

☐ 0 ☐ 1 ☐ 2 ☐ 3 ☐ 4

Patient weight at initiation of HCT/CT/IST: ____________ kg

Patient height at initiation of HCT/CT/IST: ____________ cm
COMORBIDITY INDEX


Was there any clinically significant co-existing disease or organ impairment as listed below at time of patient assessment prior to the preparative regimen?

- No
- Yes (indicate each comorbidity below)
- Unknown

COMORBIDITY:

<table>
<thead>
<tr>
<th>Condition</th>
<th>Definition</th>
<th>Yes</th>
<th>No</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solid tumour, previously present</td>
<td>Treated at any time point in the patient’s past history, excluding non-melanoma skin cancer. Indicate type:__________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>Crohn’s disease or ulcerative colitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatologic</td>
<td>SLE, RA, polymyositis, mixed CTD or polymyalgia rheumatica</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>Requiring continuation of antimicrobial treatment after day 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>Requiring treatment with insulin or oral hypoglycaemics but not diet alone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal: moderate/severe</td>
<td>Serum creatinine &gt; 2 mg/dL or &gt;177 μmol/L, on dialysis, or prior renal transplantation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic: mild</td>
<td>Chronic hepatitis, bilirubin between Upper Limit Normal (ULN) and 1.5 x ULN, or AST/ALT between ULN and 2.5 x ULN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic: moderate/severe</td>
<td>Liver cirrhosis, bilirubin greater than 1.5 x ULN, or AST/ALT greater than 2.5 x ULN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>Coronary artery disease, congestive heart failure, myocardial infarction, EF ≤ 50%, or shortening fraction in children (&lt;28%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>Transient ischaemic attack or cerebrovascular accident</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart valve disease</td>
<td>Except mitral valve prolapse</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary: moderate</td>
<td>DLco and/or FEV1 66-80%, or dyspnoea on slight activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary: severe</td>
<td>DLco and/or FEV1 ≤ 65%, or dyspnoea at rest or requiring oxygen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td>Patients with body mass index &gt; 35 kg/m²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peptic ulcer</td>
<td>Requiring treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric disturbance</td>
<td>Depression or anxiety requiring psychiatric consultation or treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COMORBIDITY INDEX continued

Was there any additional major clinical abnormality not listed above and present prior to the preparative regimen?

- No
- Yes; specify: 

Were there any autoimmune diseases?

- No
- Yes; specify: 

Date: _ _ _ / _ _ _ / _ _ _ (YYYY/MM/DD)

COMORBIDITY INDEX
Inborn Errors of Immunity only

<table>
<thead>
<tr>
<th>COMORBIDITY:</th>
<th>Definition:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic lung disease</td>
<td>Bronchiectasis, interstitial pneumonitis, GLILD, oxygen dependency, structural lung disease (e.g. pneumatoceles)</td>
</tr>
<tr>
<td>Previous haematological malignancy</td>
<td>Leukaemia, lymphoma, myelodysplastic syndrome (MDS)</td>
</tr>
<tr>
<td>Failure to thrive</td>
<td>Weight &lt;3rd percentile or requirement for (par)enteral feeding</td>
</tr>
<tr>
<td>Active infection at HCT</td>
<td>Any infection requiring therapy in the immediate pre HCT period</td>
</tr>
<tr>
<td>Lymphoproliferation</td>
<td>i.e. splenomegaly, organ specific lymphoproliferation</td>
</tr>
<tr>
<td>Pre-HCT organ impairment</td>
<td>Infectious or non-infectious (including neurologic)</td>
</tr>
<tr>
<td>Autoimmunity/autoinflammation</td>
<td>Active at HCT (includes patients in remission but on immunomodulatory treatment within 3 months before HCT)</td>
</tr>
</tbody>
</table>
SARS-CoV-2 RELATED QUESTIONS

Did the patient have a symptomatic SARS-CoV-2 infection (positive PCR or antigen test) in the 3 months prior to the day of treatment? Note: do not report here if the infection was asymptomatic.
- [ ] No
- [ ] Yes; Date: __/__/____ (YYYY/MM/DD)

Did the patient have an ongoing SARS-CoV-2 infection (positive PCR or antigen test) at the moment of the start of the conditioning regimen?
- [ ] No
- [ ] Yes

END OF GENERAL SECTION

TO COMPLETE DISEASE STATUS AT HCT/CT/IST REPORT, PLEASE FILL IN THE APPLICABLE DIAGNOSE-SPECIFIC QUESTIONS ATTACHED
### Status at treatment

Complete only for one main indication diagnosis for which this HCT/CT/IST is given.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Go to page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACUTE LEUKAEMIAS</td>
<td>6</td>
</tr>
<tr>
<td>CHRONIC LEUKAEMIAS - Chronic Myelogenous Leukaemias (CML)</td>
<td>7</td>
</tr>
<tr>
<td>CHRONIC LEUKAEMIAS - Chronic Lymphocytic Leukaemias (CLL)</td>
<td>8</td>
</tr>
<tr>
<td>CHRONIC LEUKAEMIAS - Prolymphocytic (PLL) and Other Chronic Leukaemias</td>
<td>9</td>
</tr>
<tr>
<td>LYMPHOMAS</td>
<td>10</td>
</tr>
<tr>
<td>MYELODYSPLASTIC SYNDROMES (MDS)</td>
<td>11</td>
</tr>
<tr>
<td>COMBINED MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS (MDS/MPN)</td>
<td>12</td>
</tr>
<tr>
<td>MYELOPROLIFERATIVE NEOPLASMS (MPN)</td>
<td>13</td>
</tr>
<tr>
<td>PLASMA CELL DISORDERS (PCD) including MULTIPLE MYELOMA (MM)</td>
<td>15</td>
</tr>
<tr>
<td>SOLID TUMOURS</td>
<td>16</td>
</tr>
<tr>
<td>AUTOIMMUNE DISEASES</td>
<td>17</td>
</tr>
<tr>
<td>HAEMOGLOBINOPATHIES</td>
<td>18</td>
</tr>
</tbody>
</table>
ACUTE LEUKAEMIAS
Status at treatment

Status:
- Primary induction failure
- 1st complete haematological remission (CR)
- 1st relapse
- 2nd complete haematological remission (CR)
- 2nd relapse
- 3rd or higher complete haematological remission (CR)
- 3rd or higher relapse
- Unknown

Number of induction courses: ___  Unknown

Date of the last relapse before this treatment: _____ / _____ / _____ (YYYY/MM/DD)  Not applicable (if applicable)

CD19 expression at the last relapse:  Positive  Negative  Not evaluated

Bone marrow burden (% blasts): ___  %  Not evaluated  Unknown

Involvement at time of treatment:
- Medullary only
- Extra-medullary only
- Both, medullary and extra-medullary
- Unknown

Organs involved at time of treatment:

Skin:  No  Yes  Not evaluated
CNS:  No  Yes  Not evaluated
Testes/Ovary:  No  Yes  Not evaluated
Other; specify: __________________

Complete this section only if the disease status is CR

Minimal residual disease (MRD) at initiation of treatment:
- Positive
- Negative
- Not evaluated

Date MRD status evaluated: _____ / _____ / _____ (YYYY/MM/DD)

Sensitivity of MRD assay:
- <10^-5
- <10^-4
- <10^-3
- Other; specify: ________________

Method used:
- PCR
- Flow cytometry
- Other; specify: __________________
# CHRONIC LEUKAEMIAS

## Chronic Myelogenous Leukaemias (CML) - Status at treatment

### Status:

- **Chronic phase (CP)**
  - **Number:**
    - 1<sup>st</sup>
    - 2<sup>nd</sup>
    - 3<sup>rd</sup> or higher
    - Unknown
  - **Haematological remission:**
    - No
    - Yes
    - Not evaluated
    - Unknown
  - **Cytogenetic remission:**
    - No
    - Yes
    - Not evaluated
    - Unknown
  - **Molecular remission:**
    - No
    - Yes
    - Not evaluated
    - Unknown

- **Accelerated phase**
  - **Number:**
    - 1<sup>st</sup>
    - 2<sup>nd</sup>
    - 3<sup>rd</sup> or higher
    - Unknown

- **Blast crisis**
  - **Number:**
    - 1<sup>st</sup>
    - 2<sup>nd</sup>
    - 3<sup>rd</sup> or higher
    - Unknown
STATUS:

- Complete remission (CR)
- Partial remission (PR)
- Stable disease (SD)
- Relapse (untreated)
- Progressive disease (PD)
- Never treated
- Unknown

**Complete this section only if the disease status is CR**

**Minimal residual disease (MRD) at initiation of treatment:**

(by FACS or PCR)

- Negative
- Positive
- Not evaluated
CHRONIC LEUKAEMIAS
Prolymphocytic (PLL) and Other Chronic Leukaemias
Status at treatment

Status:
☐ Complete remission (CR)
☐ Partial remission (PR)
☐ Stable disease (SD)
☐ Relapse (untreated)
☐ Progressive disease (PD)
☐ Never treated
☐ Unknown
# LYMPHOMAS
Status at treatment

## Status:
- Complete remission (CR)
  - Unconfirmed (CRU*)
  - Confirmed
  
  *CRU: Complete response with persistent scan abnormalities of unknown significance
- Partial response (PR) with or without prior CR
- Stable disease
- Untreated relapse from previous CR / untreated progression from previous PR
  - Histopathological verification of relapse: No, Yes
- Chemorefractory relapse or progression, including primary refractory disease
  - Histopathological verification of relapse: No, Yes
- Disease status unknown

## Technique used for disease assessment:
- CT scan
- PET
- MRI

## Parameters for international prognostic indices:

### Age at diagnosis:

Age at diagnosis: ________ years *(this is automatically calculated in the database)*

### LDH levels elevated:

LDH levels elevated: No, Yes, Not evaluated

### Ann Arbor staging:

Ann Arbor staging: I, II, III, IV, Not evaluated

### ECOG performance status:

ECOG performance status: 0, 1, 2, 3, 4, Not evaluated

### > 1 extranodal site involved:

> 1 extranodal site involved: No, Yes, Not evaluated

### > 4 nodal sites involved:

> 4 nodal sites involved: No, Yes, Not evaluated

### Hemoglobin < 120g/L:

Hemoglobin < 120g/L: No, Yes, Not evaluated

### White Blood Cell count:

White Blood Cell count: ________ x 10^9 cells/L, Not evaluated
# MYELODYSPLASTIC SYNDROMES (MDS)
## Status at treatment

### Classification at treatment (WHO 2016):
- [ ] MDS with single lineage dysplasia (MDS-SLD)
- [ ] MDS with ring sideroblasts (MDS-RS)
- [ ] Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
- [ ] MDS with multilineage dysplasia (MDS-MLD)
- [ ] MDS-RS with single lineage dysplasia (MDS-RS-SLD)
- [ ] MDS-RS with multilineage dysplasia (MDS-RS-MLD)
- [ ] MDS with excess blasts (EB)-1
- [ ] MDS with excess blasts (EB)-2
- [ ] Refractory cytopenia of childhood
- [ ] MDS unclassifiable (MDS-U)

### Status:
- [ ] Complete remission (CR)
  - Number: [ ] 1st
  - [ ] 2nd
  - [ ] 3rd or higher
  - [ ] Unknown
- [ ] Improvement but no CR
- [ ] Primary refractory phase (no change)
- [ ] Relapse
  - Number: [ ] 1st
  - [ ] 2nd
  - [ ] 3rd or higher
  - [ ] Unknown
- [ ] Progression/Worsening
- [ ] Never treated (supportive care or treatment without chemotherapy)
- [ ] Unknown
## Combined Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN) - Status at treatment

### Classification:

- [ ] Chronic myelomonocytic leukaemia (CMMoL, CMML): **CMML type:**
  - [ ] Myelodysplastic
  - [ ] Myeloproliferative

  **WHO subclassification (2016):**
  - [ ] CMML-0
  - [ ] CMML-1
  - [ ] CMML-2
  - [ ] Unknown

- [ ] Juvenile myelomonocytic leukaemia (JCMMoL, JMML, JCML, JCMML)
- [ ] Atypical CML (t(9;22) negative and BCR-ABL1 negative)
- [ ] MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
- [ ] MDS/MPN unclassifiable

### Status:

- [ ] Complete remission (CR)
  - [ ] 1st
  - [ ] 2nd
  - [ ] 3rd or higher
  - [ ] Unknown

- [ ] Improvement but no CR

- [ ] Primary refractory phase (no change)

- [ ] Relapse
  - [ ] 1st
  - [ ] 2nd
  - [ ] 3rd or higher
  - [ ] Unknown

- [ ] Progression/Worsening

- [ ] Never treated (supportive care or treatment without chemotherapy)

- [ ] Unknown
Classification at treatment (WHO 2016):

- [ ] Primary myelofibrosis (Chronic idiopathic myelofibrosis; fibrosis with myeloid metaplasia)
- [ ] Secondary myelofibrosis (Transformed to myelofibrosis from PV/ET)
- [ ] Polycythaemia vera (PV)
- [ ] Essential or primary thrombocythaemia (ET)
- [ ] Hyper eosinophilic syndrome (HES)
- [ ] Chronic eosinophilic leukaemia (CEL)
- [ ] Chronic neutrophilic leukaemia
- [ ] Systemic mastocytosis
- [ ] Mast cell leukaemia
- [ ] Mast cell sarcoma
- [ ] MPN not otherwise specified
- [ ] Myeloid and lymphoid neoplasms with FGFR1 abnormalities (Stem cell leukaemia-lymphoma syndrome, 8p11 syndrome)
- [ ] Myeloid and lymphoid neoplasms with PDGFRA rearrangement
- [ ] Myeloid and lymphoid neoplasms with PDGFRB rearrangement
- [ ] Myeloid and lymphoid neoplasms with PCM1-JAK2 rearrangement
- [ ] Transformed to AML
- [ ] Other; specify: ______________

Status:

- [ ] Complete remission (CR)  
  - Number:  
    - [ ] 1\textsuperscript{st}
    - [ ] 2\textsuperscript{nd}
    - [ ] 3\textsuperscript{rd} or higher
    - [ ] Unknown

- [ ] Improvement but no CR
- [ ] Primary refractory phase (no change)

- [ ] Relapse  
  - Number:  
    - [ ] 1\textsuperscript{st}
    - [ ] 2\textsuperscript{nd}
    - [ ] 3\textsuperscript{rd} or higher
    - [ ] Unknown

- [ ] Progression/Worsening
- [ ] Never treated (supportive care or treatment without chemotherapy)
- [ ] Unknown
**MYELOPROLIFERATIVE NEOPLASMS (MPN)**

**Status at treatment**

| Blast count (peripheral blood): | _______ % | ☐ Not evaluated | ☐ Unknown |
| Spleen size: | _______ cm (below costal margin) | ☐ Not evaluated | ☐ Unknown |
| Spleen span in ultrasound or CT scan: | _______ cm (maximum diameter) | ☐ Not evaluated | ☐ Unknown |
| **JAK inhibitor exposure between diagnosis and treatment:** | | | |
| ☐ No | | | |
| ☐ Yes | | | |
| ☐ Unknown | | | |
| **Was a JAK inhibitor continued during conditioning?** | | | |
| ☐ No | | | |
| ☐ Yes: | Dose: | _______ mg/day | |
| | Start date: | _______ / ______ / ______ (YYYY/MM/DD) | |
| | End date: | _______ / ______ / ______ (YYYY/MM/DD) | |
| **Response status:** | | | |
| ☐ Spleen response | | | |
| ☐ No response/loss of response | | | |
| ☐ Primary resistance | | | |
| ☐ Unknown | | | |

**Myelofibrosis only:**

| DIPSS Risk score at treatment: | | | |
| ☐ Low risk | | | |
| ☐ Intermediate - 1 | | | |
| ☐ Intermediate - 2 | | | |
| ☐ High risk | | | |
| ☐ Not evaluated | | | |
| ☐ Unknown | | | |
| **MIPSS70 score at treatment:** | | | |
| ☐ Low risk | | | |
| ☐ Intermediate | | | |
| ☐ High risk | | | |
| ☐ Not evaluated | | | |
| ☐ Unknown | | | |

**Secondary myelofibrosis only (post-ET MF, post-PV MF):**

| MYSEC-PM score at time of secondary MF diagnosis: | | | |
| ☐ Low risk | | | |
| ☐ Intermediate - 1 | | | |
| ☐ Intermediate - 2 | | | |
| ☐ High risk | | | |
| ☐ Not evaluated | | | |
| ☐ Unknown | | | |
## PLASMA CELL DISORDERS (PCD) incl. MULTIPLE MYELOMA (MM)

### Status at treatment

<table>
<thead>
<tr>
<th>Status</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRD negative CR</td>
<td></td>
</tr>
<tr>
<td>Stringent complete remission (sCR)</td>
<td></td>
</tr>
<tr>
<td>Complete remission (CR)</td>
<td></td>
</tr>
<tr>
<td>Very good partial remission (VGPR)</td>
<td></td>
</tr>
<tr>
<td>Partial remission (PR)</td>
<td></td>
</tr>
<tr>
<td>Stable disease / No change</td>
<td></td>
</tr>
<tr>
<td>Progression</td>
<td></td>
</tr>
<tr>
<td>Never treated</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

*Number: [ ] 1<sup>st</sup> [ ] 2<sup>nd</sup> [ ] 3<sup>rd</sup> or higher [ ] Unknown*
**SOLID TUMOURS**

**Status at treatment**

<table>
<thead>
<tr>
<th>Status</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant</td>
<td></td>
</tr>
<tr>
<td>Never treated (upfront)</td>
<td></td>
</tr>
<tr>
<td>Stable disease/no response</td>
<td></td>
</tr>
<tr>
<td>Complete remission (CR)</td>
<td></td>
</tr>
<tr>
<td>Unconfirmed (UCR*)</td>
<td></td>
</tr>
<tr>
<td>Confirmed</td>
<td></td>
</tr>
</tbody>
</table>

*UCR: complete response with persistent scan abnormalities of unknown significance*

<table>
<thead>
<tr>
<th>Complete remission (CR)</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unconfirmed (UCR*)</td>
<td>1st</td>
</tr>
<tr>
<td>Confirmed</td>
<td>2nd</td>
</tr>
<tr>
<td></td>
<td>3rd or higher</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
</tr>
</tbody>
</table>

| 1st partial response (PR1)                   |        |
| Relapse                                     |        |
|                                            |        |

<table>
<thead>
<tr>
<th>Sensitivity to chemotherapy:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitive</td>
<td></td>
</tr>
<tr>
<td>Resistant</td>
<td></td>
</tr>
<tr>
<td>Untreated</td>
<td></td>
</tr>
</tbody>
</table>

| 1st partial response (PR1)                   |        |
| Relapse                                     |        |
|                                            |        |

<table>
<thead>
<tr>
<th>Sensitivity to chemotherapy:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitive</td>
<td></td>
</tr>
<tr>
<td>Resistant</td>
<td></td>
</tr>
<tr>
<td>Untreated</td>
<td></td>
</tr>
</tbody>
</table>

| Progressive disease (PD)                    |        |
| Unknown                                     |        |

**Complete this section only if the disease status is not CR**

**Organ involvement at time of this treatment:**
- Nodes below diaphragm
- Nodes above diaphragm
- CNS
- Liver
- Bone
- Lung
- Soft tissue
- Other; specify: ________________

**Germ cell tumours only:**

**Risk category at disease recurrence (or platinum refractoriness) following first line chemotherapy:**

*Note: according to International Prognostic Factors Study Group classification published in 2010.*

- Very low
- Low
- Intermediate
- High
- Very high
- Not evaluated
# AUTOIMMUNE DISEASES
## Status at Mobilisation

### Systemic sclerosis only:

**SSc subset:**
- Diffuse cutaneous
- Limited cutaneous
- Sine scleroderma
- Other; specify: ___________

**Assessments at time of mobilisation (within 3 months before mobilisation):**

- Creatinine Clearance (Cockroft formula): __________ ml/min  □ Unknown
- Proteinuria: __________ g/24hrs  □ Unknown
- Modified Rodnan Skin Score (0-51): __________  □ Unknown
- DLCO (corrected for Hb): __________%  □ Unknown
- Mean Pulmonary Arterial Systolic Pressure [PASP] (from right heart catheterisation): __________ mm Hg
- GI Involvement:  □ No  □ Yes  □ Not evaluated  □ Unknown

### Systemic lupus erythematosus only:

**Assessments at time of mobilisation (within 3 months before mobilisation):**

- SLEDAI-2K Score: __________  □ Not evaluated  □ Unknown

### Multiple sclerosis only:

**Status at time of mobilisation (within 3 months before mobilisation):**
- Primary progressive
- Secondary progressive
- Relapsing/remitting
- Other; specify: ___________

**Assessments at time of mobilisation (within 3 months before mobilisation):**

- EDSS (1-10): __________  □ Not evaluated

- Number of gadolinium enhancing lesions present on MRI brain scan: __________  □ Unknown

### Crohn's disease only:

**Assessments at time of mobilisation (within 3 months before mobilisation):**

- CDAI (0-700): __________  □ Not evaluated  □ Unknown
- Serum albumin: __________ g/L  □ Unknown
HAEMOGLOBINOPATHIES
Status at treatment

<table>
<thead>
<tr>
<th>Ferritin level: ____ ng/mL</th>
<th>□ Not evaluated</th>
<th>□ Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of red blood cell transfusions:</td>
<td>□ &lt;20 units</td>
<td>□ 20 to 50 units</td>
</tr>
</tbody>
</table>

Liver iron concentration: ____ mg/g dry weight

Pre-existing liver disease?

□ No

□ Yes: Hepatitis: □ Absent
□ Chronic persistent hepatitis
□ Chronic active hepatitis

Liver biopsy performed? □ No

□ Yes: Liver fibrosis (Ishak staging):
□ F0 (no fibrosis)
□ F1 (partial fibrosis)
□ F2 (general fibrosis)
□ F3 (partial bridging in fibrosis)
□ F4 (general bridging in fibrosis)
□ F5 (near cirrhosis)
□ F6 (cirrhosis)

Pre-existing cardiac disease?

□ No

□ Yes: Cardiac echography ejection fraction: □ No □ Yes

Cardiovascular magnetic resonance (CMR) T2: ____ mg/g dry weight

Sickle cell disease only

Chronic transfusion program: □ No □ Yes
**Pre-treatment complications (Sickle cell disease only):**

(check all that apply)

<table>
<thead>
<tr>
<th>Condition</th>
<th>No</th>
<th>Yes</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrovascular disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal Doppler</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemorrhage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arteriopathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moyamoya disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silent infarcts</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Renal involvement**

- Microalbumin level: ______ mg/g  □ Not evaluated
- Glomerular filtration rate: ______ mL/min/1.73m²  □ Not evaluated
- Avascular necrosis:  □ No □ Yes □ Not evaluated

**Hyperhaemolysis or autoimmune haemolytic anaemia:**

□ No  □ Yes: □ Hyperhaemolysis □ Autoimmune haemolytic anaemia □ Not evaluated

**Other SCD related complications**

<table>
<thead>
<tr>
<th>Condition</th>
<th>No</th>
<th>Yes</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute chest syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaso-occlusive crisis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Priapism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary artery pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Endocrinopathies pre-existing to HCT (Thalassemia only):**

<table>
<thead>
<tr>
<th>Condition</th>
<th>No</th>
<th>Yes</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothyroidism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoparathyroidism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoporosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gonadal dysfunction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Growth impairment</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>